首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Biotin interference in immunoassays based on biotin-strept(avidin) chemistry: An emerging threat
Authors:John HT Luong  Keith B Male  Jeremy D Glennon
Institution:1. University College Cork, Irish Separation Science Cluster ISSC Ireland, Innovative Chromatography Group, Western Rd, Cork T12 YN60, Ireland;2. University College Cork, School of Chemistry, College Road, Cork T12 YN60, Ireland;3. CCA Lab, Hampstead, Quebec H3X 1X5, Canada
Abstract:Biotinylated antibodies/antigens are currently used in many immunoassay formats in clinical settings for diversified analytes and biomarkers to offer high detection selectivity and sensitivity. Biotin cannot be synthesized by mammals and must be taken as an essential supplement. Normal intake of biotin from various foods and milk causes no effect on the streptavidin/biotin-based immunoassays. However, overconsumption of biotin (daily doses 100–300 mg) poses a significant problem for immunoassays using the biotin-strept(avidin) pair. Biotin interferences are noted in immunoassays of thyroid markers, drugs, hormones, cancer markers, the biomarker for cardiac function (β–human chorionic gonadotropin), etc. The biotin level required for serious interference in test results varies significantly from test to test and cannot easily be predicted. Immunoassay manufacturers with technologies based on strept(avidin)-biotin binding must investigate the interference from biotin (up to at least 1200 ng/mL or 4.9 μM of biotin) in various formats. There is no concrete solution to circumvent the biotin interference encountered in blood samples, short of biotin removal. Considering the short half-life of biotin in the human body, patients must stop taking biotin supplements for >48 h before the test. However, this scenario is not considered for patients in emergency situations or those with biotinidase deficiency, mitochondrial metabolic disorders or multiple sclerosis. Apparently, a rapid analytical procedure for biotin is urgently needed to quantify for its interference in immunoassays using strep(avidin)-biotin chemistry. To date, there is no quick and reliable procedure for the detection of biotin at below nanomolar levels in blood and biological samples.Traditional lab-based techniques including HPLC/MS-MS cannot process an enormous number of public samples. Biosensors with high detection sensitivity, miniaturization, low cost, and multiplexing have the potential to address this issue.
Keywords:Corresponding author at: University College Cork  Irish Separation Science Cluster ISSC Ireland  Innovative Chromatography Group  Western Rd  Cork T12 YN60  Ireland    Biotin interference  Avidin/streptavidin  Immunoassays  Sandwiched assay  Competitive assay  Falsely negative  Falsely positive  Biotin removal
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号